Harvard Medical School
Lincoln, MA, United States
Dr. Matthew Menard graduated summa cum laude, phi beta kappa and with departmental high honors from Middlebury College. He attended Harvard Medical School and received his general surgery training at the Massachusetts General Hospital and vascular surgery fellowship training at the Brigham and Women’s Hospital (BWH). He is currently Co-Director of Endovascular Surgery and the Vascular and Endovascular Surgery Fellowship Director at the Brigham and Women’s Hospital and an Associate Professor of Surgery at Harvard Medical School. His clinical practice spans the gamut of vascular surgical disease, with a focus on chronic limb threatening ischemia.
Dr. Menard conceived and is a National Principal Investigator of the BEST-CLI Trial, an NIH-sponsored and FDA-endorsed investigation of the comparative-effectiveness of open surgery and endovascular therapy for critical limb ischemia (CLI). BEST-CLI is a randomized, controlled trial examining treatment efficacy, functional outcomes, cost and cost-effectiveness associated with endovascular or open surgical revascularization in patients with CLI. The trial involved more than 150 clinical sites in the United States, Canada, Finland, Italy and New Zealand. Dr. Menard, along with collaborators at Boston Medical Center, Massachusetts General Hospital and Kolding/Lillebælt Hospital in Denmark, recently received a $4 million grant from the Novo Nordisk Foundation to extend the analysis of this landmark trial, establish a core angiographic imaging laboratory at BWH and investigate the health economics of CLTI care globally.
Disclosure information not submitted.
Thursday, August 8, 2024
9:10 AM – 10:30 AM East Coast USA Time
Aorobifemoral bypass is the most durable approach for aortoiliac disease
Thursday, August 8, 2024
1:30 PM – 1:38 PM East Coast USA Time
Thursday, August 8, 2024
2:24 PM – 2:40 PM East Coast USA Time